SCHEMBL30830649

SCHEMBL30830649

COc1cc(C2CCC3(CC2)CCN(C(=O)c2ccc([C@H]4C[C@@H](Nc5cnn(C)c(=O)c5Br)CN(C)C4)cc2)CC3)ccc1C1CCC(=O)NC1=O

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 12/20 0.46
▸ BRD9 Q9H8M2 4/20 0.46
▸ BRD1 O95696 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ BRPF1 P55201 1/20 0.46
▸ BPTF Q12830 1/20 0.46
▸ KAT2A Q92830 1/20 0.46
▸ BRD7 Q9NPI1 1/20 0.46
▸ BAZ2B Q9UIF8 1/20 0.46
▸ BRPF3 Q9ULD4 1/20 0.46
▸ SOS1 Q07889 2/20 0.32
▸ LRRK2 Q5S007 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ DDB1 Q16531 1/20 0.30
▸ CRBN Q96SW2 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830534 0.94 KAT2B (0.37) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830989 0.93 KAT2B (0.45) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830748 0.93 KAT2B (0.46) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830558 0.92 KAT2B (0.47) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830850 0.91 KAT2B (0.53) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831030 0.90 KAT2B (0.44) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831061 0.89 KAT2B (0.46) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830711 0.89 KAT2B (0.44) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831051 0.87 KAT2B (0.45) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830713 0.86 KAT2B (0.49) KAT2BBRD9BRD1ACHEBRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback